Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by 4Justiceon Aug 17, 2021 5:14pm
162 Views
Post# 33720306

OBLIGATIONS OF $131, 564 MILLIONS IN THE NEXT 5 YEARS

OBLIGATIONS OF $131, 564 MILLIONS IN THE NEXT 5 YEARS

Tabular Disclosure of Contractual Obligations 

The timing and expected contractual outflows required to settle our financial obligations recognized in the consolidated statement of financial position at June 30, 2021 are presented in the table below:

 

 

 

 

 

 

 

Contractual Cash flows

 

 

 

Carrying amount

 

 

Less than

1 year

 

 

1-3

years

 

 

3 - 5

years

 

 

More than

5 years

 

 

Total

 

Accounts payable and

   accrued liabilities 1)

 

$

9,375

 

 

$

9,375

 

 

$

 

 

$

 

 

$

 

 

$

9,375

 

Other Long-term liabilities

 

 

103

 

 

 

 

 

 

50

 

 

 

50

 

 

 

211

 

 

 

311

 

Lease liabilities

 

 

24,136

 

 

 

5,461

 

 

 

10,874

 

 

 

10,461

 

 

 

19,783

 

 

 

46,579

 

Long-term debt 2)

 

 

41,750

 

 

 

6,545

 

 

 

46,286

 

 

 

 

 

 

 

 

 

52,831

 

Provisions 3)

 

 

21,928

 

 

 

3,097

 

 

 

9,171

 

 

 

8,668

 

 

 

1,532

 

 

 

22,468

 

 

 

$

97,292

 

 

$

24,478

 

 

$

66,381

 

 

$

19,179

 

 

$

21,526

 

 

$

131,564

 

 

1)Short-term portions of the royalty payment obligations and of other employee benefit liabilities are included in the accounts payable and accrued liabilities.

2) Under the terms of the consolidated loan agreement we have with SALP, SALP may decide to cancel a portion of the principal value of the loans as payment upon the exercise of their 168,735 warrants #10 and 3,947,367 November 2020 warrants. The maximum repayment due on the loan has been included in the above table.

3) Provisions include the non-lease portion of the commitment under the CDMO contract that we determined to be an onerous contract.

 
<< Previous
Bullboard Posts
Next >>